Oncoinvent Unveils Encouraging Results from Phase 1 Trial of Radspherin for Ovarian Cancer Treatment Oncoinvent ASA announces promising results from a Phase 1 trial of Radspherin, showcasing its potential in treating ovarian cancer. This marks a key advancement in cancer therapy.

Oncoinvent Unveils Encouraging Results from Phase 1 Trial of Radspherin for Ovarian Cancer Treatment #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent Announces Encouraging Results from Phase 1 Trial of Radspherin® Targeting Ovarian Cancer Oncoinvent ASA reveals promising data from its Phase 1 trial of Radspherin®, demonstrating potential in preventing ovarian cancer progression.

Oncoinvent Announces Encouraging Results from Phase 1 Trial of Radspherin® Targeting Ovarian Cancer #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent ASA's Strong Progress in Ovarian Cancer Research Report Oncoinvent ASA has reported significant advancements in its Phase 2 ovarian cancer trial, showcasing financial discipline and corporate development.

Oncoinvent ASA's Strong Progress in Ovarian Cancer Research Report #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent ASA Reports Progress in Ovarian Cancer Treatment and Financial Discipline Oncoinvent ASA reveals significant advancements in its ovarian cancer clinical trials while maintaining strict financial discipline. This report covers key developments and future plans.

Oncoinvent ASA Reports Progress in Ovarian Cancer Treatment and Financial Discipline #Norway #Oslo #Radspherin #Oncoinvent #OvarianCancer

BerGenBio and Oncoinvent Plan to Merge and Boost Cancer Therapy Innovations BerGenBio ASA and Oncoinvent ASA are set to merge, enhancing cancer treatment strategies with groundbreaking radiopharmaceuticals and a fully underwritten rights issue.

BerGenBio and Oncoinvent Plan to Merge and Boost Cancer Therapy Innovations #Norway #Oslo #radiopharmaceuticals #BerGenBio #Oncoinvent

BerGenBio ASA Announces Major Rights Issue to Fuel Strategic Merger with Oncoinvent ASA BerGenBio ASA has announced a fully underwritten rights issue aimed at raising NOK 130 million to support its merger with Oncoinvent ASA.

BerGenBio ASA Announces Major Rights Issue to Fuel Strategic Merger with Oncoinvent ASA #Norway #Rights_Issue #Bergen #BerGenBio #Oncoinvent

BerGenBio ASA Announces Fully Underwritten Rights Issue and Merger Plans BerGenBio ASA has unveiled a fully underwritten rights issue aimed at existing shareholders, tied to an upcoming merger with Oncoinvent ASA, raising NOK 130 million.

BerGenBio ASA Announces Fully Underwritten Rights Issue and Merger Plans #Norway #Oslo #Rights_Issue #BerGenBio #Oncoinvent

BerGenBio and Oncoinvent Plan Merger to Enhance Cancer Therapy Development BerGenBio and Oncoinvent are merging to create a robust entity that will accelerate the development of innovative cancer therapies with a combined funding strategy.

BerGenBio and Oncoinvent Plan Merger to Enhance Cancer Therapy Development #Norway #Oslo #radiopharmaceuticals #BerGenBio #Oncoinvent

Oncoinvent Reveals Promising Phase 1/2a Trial Results for Radspherin® in Colorectal Cancer Patients Oncoinvent ASA has announced significant positive results from its Phase 1/2a trial of Radspherin® for patients with colorectal peritoneal metastases, indicating improved survival rates and disease management.

Oncoinvent Reveals Promising Phase 1/2a Trial Results for Radspherin® in Colorectal Cancer Patients #Norway #Oslo #Radspherin #Colorectal_Cancer #Oncoinvent

Oncoinvent Reports Positive Results for Radspherin® in Treating Colorectal Peritoneal Metastases Oncoinvent ASA shares promising data from a Phase 1/2a trial evaluating Radspherin® for colorectal cancer metastases. Results indicate substantial potential for patient treatment.

Oncoinvent Reports Positive Results for Radspherin® in Treating Colorectal Peritoneal Metastases #Norway #Oslo #Colorectal_Cancer #Oncoinvent #Radspherin®

Oncoinvent's Ovarian Cancer Trial with Radspherin® Shows Promising Results After 18 Months Oncoinvent ASA reveals encouraging 18-month findings from its ongoing ovarian cancer trial with Radspherin®, indicating improved patient outcomes.

Oncoinvent's Ovarian Cancer Trial with Radspherin® Shows Promising Results After 18 Months #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent